In little more than five years, German biotechnology company YUMAB (a phonetic play on HUMAB (human monoclonal antibody) in which the “Y” symbolizes the antibody structure) has become a global ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

View Full Profile. Learn about our Editorial Policies. For decades, researchers fixated on the extraordinary potential nestled within the human immune system, particularly the formidable prowess of ...

Human therapeutic antibodies constitute the industry’s fastest-growing therapeutic class. In the US, more than 500 antibodies are in various stages of clinical development, and the number of ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...

The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...